Powered by the Evidence-based Practice Centers
SHARE:
FacebookTwitterFacebookPrintShare

Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women

Systematic Review ARCHIVED Sep 14, 2009

Documents

Archived: This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current.

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Excerpt

The purpose of this review is to evaluate the comparative effectiveness of tamoxifen citrate, raloxifene, and tibolone to reduce risk for primary breast cancer, assess the nature and magnitude of harms, and examine how benefits and harms vary by age, breast cancer risk status, and other factors. In addition, it examines issues related to clinical effectiveness, such as patient choice, concordance, adherence, and persistence of use, and evaluates methods to appropriately select patients for medication therapy to reduce risk of breast cancer.

Project Timeline

Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women

Jan 1, 2005
Topic Initiated
Sep 14, 2009
Systematic Review Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Systematic Review: Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/breast-cancer-medications/research

Select to copy citation